After-hours trading on Friday, Evelo Biosciences, Inc. (Nasdaq: EVLO), the stock plunged -11/56% to $10.25. It’s not clear what happened that caused the share price to fall, and investors may want to take that as a warning sign.
A clinical-stage biotechnology company creating new oral medications with systemic effects prioritizes EDP1908 as its lead clinical candidate in oncology.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The Company said that it would cease patient recruitment for Phase 1/2 clinical trial of EDP1503 and finalize the study.
It revealed on additional interim clinical data from EDP1503, treated with pembrolizumab in TNBC patients with its Phase 1/2 open study, were presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting. In the 12 patients who received EDP1503 at a higher dose, as of a cutoff date of October 30, 2020, the response rate was 17 percent, with a disease control rate of 25%.
It suggests that the small intestinal axis, SINTAXTM, can be targeted using oral, gut-restricted medicines.